Live from ASH 2023 | Ascentage Pharma Releases Encouraging L

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and...

Related Keywords

China , Beijing , Hong Kong , Henan , Rockville , California , United States , Australia , Suzhou , Jiangsu , San Diego , Chinese , American , Ascentage Pharma , Jianyong Li , Prnewswire Ascentage Pharma , Keshu Zhou , Yifan Zhai , American Society Of Hematology , Major National , Md Anderson Cancer Center , China National Medical Products Administration , National Reimbursement Drug List , Astrazeneca , Dana Farber Cancer Institute , Poster Presentation , American Society , Annual Meeting , Henan Cancer Hospital , Jiangsu Province Hospital , Chief Medical Officer , Safety Results , Heavily Pretreated Chronic Lymphocytic Leukemia , Pooled Analyses , Two Clinical , Lymphocytic Leukemia , Pacific Time , Beijing Time , Main Board , Stock Exchange , Hong Kong Limited , Major National Rd Projects , Major New Drug Projects , New Drug Incubator , Innovative Drug Programs , Major Project , Priority Review Designations , Breakthrough Therapy Designations , Drug Evaluation , Reimbursement Drug List , Orphan Drug Designation , Fast Track Designation , Orphan Designation , Pediatric Disease , Cancer Center , Mayo Clinic ,